Americas Antitrust Review 2020

Global Competition Review
October 2, 2019

"The past year witnessed the US Federal Trade Commission (FTC) and the Department of Justice (DOJ) Antitrust Division making good on promises for vigorous merger enforcement, with a sharp focus on high-tech industries, including the pharmaceutical and technology industries. Garnering significant media attention, antitrust is now mainstream, grabbing headline-worthy statements from all corners of the US government, ranging from President Trump, presidential candidates, members of Congress, state attorneys general, the Food and Drug Association, the Federal Communications Commission and, of course, the FTC and the DOJ."

Read the chapter

An extract from GCR’s Americas Antitrust Review 2020, first published in September 2019. The whole publication is available on Global Competition Review's website

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.